2. Search Result
Search Result
Results for "

hyperlipidemia

" in MedChemExpress (MCE) Product Catalog:

61

Inhibitors & Agonists

2

Inhibitory Antibodies

17

Natural
Products

7

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99822
    Recaticimab

    SHR-1209

    		 PCSK9 LDLR Metabolic Disease
    Recaticimab (SHR-1209) is an orally active humanized monoclonal antibody targeting PCSK9. Recaticimab binds PCSK9 with high affinity, increases the level of low density lipoprotein receptor on the surface of liver cells, and decreases the level of low density lipoprotein cholesterol in plasma. Recaticimab can be used in the study of hypercholesterolemia and hyperlipidemia .
    Recaticimab
  • HY-132591A
    Inclisiran sodium
    2 Publications Verification

    ALN-PCSsc sodium

    		 PCSK9 Small Interfering RNA (siRNA) Cardiovascular Disease
    Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK9. Inclisiran sodium can be used for hyperlipidemia and cardiovascular disease (CVD) research .
    Inclisiran sodium
  • HY-119858
    Acetiromate

    		Others Metabolic Disease
    Acetiromate is a thyroxine analogue. Acetiromate is an antilipidemic drug for hyperlipidemia .
    Acetiromate
  • HY-116977
    Binifibrate

    		Others Metabolic Disease
    Binifibrate is an active compound and has a beneficial effect on lipoprotein metabolism. Binifibrate can be used for the research of hyperlipidemia .
    Binifibrate
  • HY-117131
    ZINC17167211

    		PPAR Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    ZINC17167211 is a potent PPAR-α agonist (EC50=0.16 nM) that can be used in the study of diabetes, hyperlipidemia, and inflammatory diseases .
    ZINC17167211
  • HY-N13146
    Azukisaponin VI

    		Others Cardiovascular Disease
    Azukisaponin VI is an oligosaccharide isolated from Vigna angularis. Azukisaponin VI has the activity of inhibiting the synthesis of lipid peroxides and can be used in the study of hyperlipidemia .
    Azukisaponin VI
  • HY-128334
    PCSK9 modulator-2

    		PCSK9 Metabolic Disease
    PCSK9 modulator-2 (Compound 1) is a potent modulator of PCSK9 with an EC50 value of 202 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-2 has the potential for the research of hyperlipidemia .
    PCSK9 modulator-2
  • HY-146084
    PCSK9 modulator-3

    		PCSK9 Metabolic Disease
    PCSK9 modulator-3 (Compound 13) is a potent modulator of PCSK9 with an EC50 value of 2.46 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-3 has the potential for the research of hyperlipidemia .
    PCSK9 modulator-3
  • HY-146085
    PCSK9 modulator-4

    		PCSK9 Metabolic Disease
    PCSK9 modulator-4 (Compound 21) is a potent modulator of PCSK9 with an EC50 value of 0.15 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-4 has the potential for the research of hyperlipidemia .
    PCSK9 modulator-4
  • HY-W004580
    5,5'-Dicarboxy-2,2'-bipyridine

    		Biochemical Assay Reagents Cardiovascular Disease
    5,5'-Dicarboxy-2,2'-bipyridine is a niacin derivative, which is promising for research of hypercholesterolemia, hyperlipidemia, and cardiovascular disease .
    5,5'-Dicarboxy-2,2'-bipyridine
  • HY-P99773
    Ongericimab

    JS002

    		 PCSK9 Cardiovascular Disease Metabolic Disease
    Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .
    Ongericimab
  • HY-132591
    Inclisiran

    ALN-PCSsc

    		 PCSK9 Small Interfering RNA (siRNA) Cardiovascular Disease
    Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK9. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research .
    Inclisiran
  • HY-143221
    AS-Inclisiran sodium

    		PCSK9 Cardiovascular Disease
    AS-Inclisiran sodium is the antisense of Inclisiran. Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research .
    AS-Inclisiran sodium
  • HY-135592
    LY88074 Methyl ether

    		Estrogen Receptor/ERR Endocrinology
    LY88074 Methyl ether (Example 2) is useful for the inhibition of the various estrogen deficient conditions, which are associated with estrogendeprivation syndrome including osteoporosis and hyperlipidemia .
    LY88074 Methyl ether
  • HY-135583
    LY88074 Trimethyl ether

    		Estrogen Receptor/ERR Endocrinology
    LY88074 Trimethyl ether (Example 1) is useful for the inhibition of the various estrogen deficient conditions, which are associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia .
    LY88074 Trimethyl ether
  • HY-150223
    GalNAc unconjugated/naked Inclisiran
    1 Publications Verification

    		 PCSK9 Small Interfering RNA (siRNA) Cardiovascular Disease
    GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA (siRNA) without GalNAc conjugation. GalNAc unconjugated/naked Inclisiran inhibits the transcription of PCSK-9, and can be used for hyperlipidemia and cardiovascular disease (CVD) research .
    GalNAc unconjugated/naked Inclisiran
  • HY-19425
    NS-220

    		PPAR Metabolic Disease
    NS-220 is an orally active PPARα agonist with high subtype selectivity, with EC50 values of 1.9×10 -8 M, 9.6×10 -6 M and >10 -4 M for PPARα, PPAR γ and PPARδ, respectively. NS-220 is used in the research for hyperlipidemia or metabolic disorders in type-2 diabetes .
    NS-220
  • HY-106818A
    Monatepil maleate

    AJ-2615

    		 Acyltransferase Calcium Channel Cardiovascular Disease Metabolic Disease
    Monatepil maleate (AJ-2615) is a potent and orally active Ca 2+-channel antagonist and a noncompetitive ACAT inhibitor. Monatepil maleate decreases blood pressure and improves plasma lipid metabolism. Monatepil maleate has the potential for the research of hyperlipidemia .
    Monatepil maleate
  • HY-142917
    THR-β agonist 4

    		Others Metabolic Disease
    THR-β agonist 4 is a potent agonist of THR-β. THR-β agonist 4 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021143706A1, compound 72) .
    THR-β agonist 4
  • HY-143613
    THR-β agonist 2

    		Others Metabolic Disease
    THR-β agonist 2 is a potent agonist of THR-β. THR-β agonist 2 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021121210A1, compound 3) .
    THR-β agonist 2
  • HY-143614
    THR-β agonist 3

    		Others Metabolic Disease
    THR-β agonist 3 is a potent agonist of THR-β. THR-β agonist 3 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021129827A1, compound 6) .
    THR-β agonist 3
  • HY-163794
    DC371739

    		ANGPTL PCSK9 Metabolic Disease
    DC371739 is a potent and orally activity PCSK9 inhibitor. DC371739 decreases the mRNA expression of PCSK9 and ANGPTL3. DC371739 decreases the protein expression of PCSK9 and increases the protein expression of LDLR. DC371739 has the potential for the research of hyperlipidemia .
    DC371739
  • HY-152221
    PCSK9-IN-10

    		PCSK9 Cardiovascular Disease Metabolic Disease
    PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia .
    PCSK9-IN-10
  • HY-147246
    Berberine ursodeoxycholate

    HTD1801; BUDCA

    		 Others Metabolic Disease
    Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes .
    Berberine ursodeoxycholate
  • HY-N0236
    Corylin
    5 Publications Verification

    		 Antibiotic STAT Infection Metabolic Disease Cancer
    Corylin is an orally active flavonoid anti-inflammatory and osteogenic agent that inhibits IL-6-induced STAT3 promoter activity and STAT3 phosphorylation. Corylin also has anticancer, antiatherosclerotic, and ameliorating activity in hyperlipidemia and insulin resistance, inducing adipocyte browning and lipolysis through SIRT1 or β3-AR-dependent pathways .
    Corylin
  • HY-164853
    Kanglexin

    		Pyroptosis NOD-like Receptor (NLR) ERK FGFR AMPK Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis .
    Kanglexin
  • HY-N13083
    PCSK9-IN-28

    		PCSK9 Cardiovascular Disease
    PCSK9-IN-28 (Compound C11) is a PCSK9 inhibitor that can be isolated from Euphorbia esula. By binding to HNF1α, PCSK9-IN-28 inhibits PCSK9 transcription by binding to HNF1α and affecting its nuclear distribution, thereby enhancing LDLR and promoting LDL uptake. PCSK9-IN-28 exhibits significant lipid-lowering activity in the high-fat diet (HFD) mouse model and can be used in the study of hyperlipidemia .
    PCSK9-IN-28
  • HY-N0236R
    Corylin (Standard)

    		Antibiotic STAT Infection Metabolic Disease Cancer
    Corylin (Standard) is the analytical standard of Corylin. This product is intended for research and analytical applications. Corylin is an orally active flavonoid anti-inflammatory and osteogenic agent that inhibits IL-6-induced STAT3 promoter activity and STAT3 phosphorylation. Corylin also has anticancer, antiatherosclerotic, and ameliorating activity in hyperlipidemia and insulin resistance, inducing adipocyte browning and lipolysis through SIRT1 or β3-AR-dependent pathways .
    Corylin (Standard)
  • HY-B1061
    Nicotinic acid N-oxide

    		Drug Derivative Cardiovascular Disease
    Nicotinic acid N-oxide can be used for research on hyperlipidemia.
    Nicotinic acid N-oxide
  • HY-164740
    Plozasiran

    ARO-APOC3

    		 Apolipoprotein Metabolic Disease
    Plozasiran is an siRNA targeting APOC3 for the study of mixed hyperlipidemia.
    Plozasiran
  • HY-164740A
    Plozasiran sodium

    ARO-APOC3 sodium

    		 Apolipoprotein Metabolic Disease
    Plozasiran sodium is an siRNA targeting APOC3 for the study of mixed hyperlipidemia.
    Plozasiran sodium
  • HY-14935
    Sodelglitazar

    GW 677954

    		 Endogenous Metabolite Metabolic Disease
    Sodelglitazar (GW 677954) serves as a PPAR agonist with potential applications in the treatment of hyperlipidemia and type 2 diabetes.
    Sodelglitazar
  • HY-B1068
    Tyloxapol
    4 Publications Verification

    		 Biochemical Assay Reagents Metabolic Disease
    Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type, used as a surface active stabilizer. Tyloxapol is used to induce hyperlipidemia in animals .
    Tyloxapol
  • HY-101637
    Reglitazar

    JT 501

    		 PPAR Metabolic Disease
    Reglitazar is an agonist for peroxisome proliferator-activated receptor α and β (PPAR α and PPAR β), which enhances insulin sensitivity, lowers blood glucose and regulates blood lipid levels .
    Reglitazar
  • HY-N0799
    Protodioscin

    		Endogenous Metabolite Cardiovascular Disease Cancer
    Protodioscin, a major steroidal saponin in Trigonella foenum-graecum Linn., has been shown to exhibit multiple biological actions, such as anti-hyperlipidemia, anti-cancer, sexual effects and cardiovascular properties.
    Protodioscin
  • HY-148874
    FXR antagonist 2

    		FXR Metabolic Disease
    FXR antagonist 2 (compound A-26) is a diarylamide derivative, as well as a moderate FXR antagonist. FXR antagonist 2 can be used in the study of hyperlipidemia and type 2 diabetes .
    FXR antagonist 2
  • HY-N0458
    Pedunculoside
    1 Publications Verification

    		 Fatty Acid Synthase (FASN) Metabolic Disease
    Pedunculoside exerts lipid-lowering effects partly through the regulation of?lipogenesis?and?fatty acid β-oxidation .
    Pedunculoside
  • HY-N0458R
    Pedunculoside (Standard)

    		Fatty Acid Synthase (FASN) Metabolic Disease
    Pedunculoside (Standard) is the analytical standard of Pedunculoside. This product is intended for research and analytical applications. Pedunculoside exerts lipid-lowering effects partly through the regulation of lipogenesis and fatty acid β-oxidation .
    Pedunculoside (Standard)
  • HY-N2953
    Borapetoside E

    		Fatty Acid Synthase (FASN) Metabolic Disease
    Borapetoside E can be isolated from T. crispa. Borapetoside E improves hyperglycemia, insulin resistance, hepatic steatosis, hyperlipidemia, and oxygen consumption in obese mice. Borapetoside E also inhibits SREBPs expression in the liver and adipose tissue .
    Borapetoside E
  • HY-B1068R
    Tyloxapol (Standard)

    		Biochemical Assay Reagents Metabolic Disease
    Tyloxapol (Standard) is the analytical standard of Tyloxapol. This product is intended for research and analytical applications. Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type, used as a surface active stabilizer. Tyloxapol is used to induce hyperlipidemia in animals .
    Tyloxapol (Standard)
  • HY-162562
    E28362

    		PCSK9 Cardiovascular Disease
    E28362 is a novel small molecule PCSK9 inhibitor. E28362 blocks the interaction between PCSK9 and LDLR, thereby preventing the degradation of LDLR and maintaining cholesterol homeostasia. E28362 is a promising lead compound for the study of hyperlipidemia and atherosclerosis .
    E28362
  • HY-N0799R
    Protodioscin (Standard)

    		Endogenous Metabolite Cancer
    Protodioscin (Standard) is the analytical standard of Protodioscin. This product is intended for research and analytical applications. Protodioscin, a major steroidal saponin in Trigonella foenum-graecum Linn., has been shown to exhibit multiple biological actions, such as anti-hyperlipidemia, anti-cancer, sexual effects and cardiovascular properties.
    Protodioscin (Standard)
  • HY-I0400
    N-Acetylneuraminic acid
    3 Publications Verification

    NANA; Lactaminic acid

    		 Tyrosinase Ras Influenza Virus Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    N-Acetylneuraminic acid (NANA; Lactaminic acid), a nonphenolic structure, is the predominant form of sialic from Collocalia esculenta. N-Acetylneuraminic acid plays a biological role in myocardial injury, melanoma and viral or bacterial infection. N-Acetylneuraminic acid inhibits melanogenesis by reducing tyrosinase activity and triggers myocardial injury in vitro and in vivo by activation of the Rho/Rho-associated signaling pathway through binding to RhoA and Cdc42. N-Acetylneuraminic acid may prevent high fat diet (HFD)-induced inflammation and oxidative stress, thereby prevents hyperlipidemia-associated inflammation and oxidative stress. N-Acetylneuraminic acid is promising for research in the field of melanoma, coronary artery, obesity-related diseases and hyperlipidemia .
    N-Acetylneuraminic acid
  • HY-139134
    S-2E

    		HMG-CoA Reductase (HMGCR) Acetyl-CoA Carboxylase Cardiovascular Disease
    S-2E is an orally active and noncompetitive HMG-CoA reductase and acetyl-CoA carboxylase inhibitor. S-2E has an anti-hyperlipidemic action. S-2E has the potential for familial hypercholesterolemia and mixed hyperlipidemia research .
    S-2E
  • HY-I0400R
    N-Acetylneuraminic acid (Standard)

    		Tyrosinase Ras Influenza Virus Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    N-Acetylneuraminic acid (Standard) is the analytical standard of N-Acetylneuraminic acid. This product is intended for research and analytical applications. N-Acetylneuraminic acid (NANA; Lactaminic acid), a nonphenolic structure, is the predominant form of sialic from Collocalia esculenta. N-Acetylneuraminic acid plays a biological role in myocardial injury, melanoma and viral or bacterial infection. N-Acetylneuraminic acid inhibits melanogenesis by reducing tyrosinase activity and triggers myocardial injury in vitro and in vivo by activation of the Rho/Rho-associated signaling pathway through binding to RhoA and Cdc42. N-Acetylneuraminic acid may prevent high fat diet (HFD)-induced inflammation and oxidative stress, thereby prevents hyperlipidemia-associated inflammation and oxidative stress. N-Acetylneuraminic acid is promising for research in the field of melanoma, coronary artery, obesity-related diseases and hyperlipidemia .
    N-Acetylneuraminic acid (Standard)
  • HY-103327
    MJ15

    		Cannabinoid Receptor Metabolic Disease
    MJ15 is a potent and selective CB1 receptor antagonist with a Ki of 27.2 pM and an IC50 of 118.9 pM for rat CB1 receptors. MJ15 exhibits potency in obesity and hyperlipidemia models. MJ15 inhibits food intake and increases in body weight in diet-induced obese rats and mice .
    MJ15
  • HY-151959
    FXR agonist 4

    		FXR Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC50 value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .
    FXR agonist 4
  • HY-14739
    Choline Fenofibrate

    ABT-335

    		 PPAR COX Cardiovascular Disease
    Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a PPAR activator with antihyperlipidemic effect .
    Choline Fenofibrate
  • HY-14739R
    Choline Fenofibrate (Standard)

    		PPAR COX Cardiovascular Disease
    Choline Fenofibrate (Standard) is the analytical standard of Choline Fenofibrate. This product is intended for research and analytical applications. Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a PPAR activator with antihyperlipidemic effect .
    Choline Fenofibrate (Standard)
  • HY-103479
    GOAT-IN-1

    		Acyltransferase Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT), which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence, Alzheimer’s disease, Parkinson’s disease, cerebrovascular dementia, cerebral apoplexy, cerebral infarction, cardic disease, some kind of tumors.
    GOAT-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: